[go: up one dir, main page]

Becker et al., 2020 - Google Patents

Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery

Becker et al., 2020

View HTML @Full View
Document ID
397863954381330438
Author
Becker L
Verdurmen W
Plückthun A
Publication year
Publication venue
BMC biology

External Links

Snippet

Background To increase the size of the druggable proteome, it would be highly desirable to devise efficient methods to translocate designed binding proteins to the cytosol, as they could specifically target flat and hydrophobic protein-protein interfaces. If this could be done …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments

Similar Documents

Publication Publication Date Title
Veggiani et al. Programmable polyproteams built using twin peptide superglues
Becker et al. Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
Malm et al. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin‐binding domain allows for affinity purification and in vivo half‐life extension
Verdurmen et al. Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems
US8043830B2 (en) Biotin-ligase system for secretion of biotinylated protein
Kornberger et al. Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin
Zhao et al. Construction and characterization of an anti‐asialoglycoprotein receptor single‐chain variable‐fragment‐targeted melittin
Seijsing et al. In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor
JP2015509501A (en) Modified microbial toxin receptor for delivering agents to cells
Barat et al. Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum
Sandersjöö et al. A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases
US20100297664A1 (en) Paratope and epitope of anti-mortalin antibody
Heads et al. Relative stabilities of IgG1 and IgG4 Fab domains: Influence of the light–heavy interchain disulfide bond architecture
Min et al. Cell‐free production and streamlined assay of cytosol‐penetrating antibodies
Galeffi et al. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems
Shaki-Loewenstein et al. A universal strategy for stable intracellular antibodies
Andrady et al. Antibody–enzyme fusion proteins for cancer therapy
Kato et al. Extensive survey of antibody invariant positions for efficient chemical conjugation using expanded genetic codes
Tomé‐Amat et al. Preparation of an engineered safer immunotoxin against colon carcinoma based on the ribotoxin hirsutellin A
Keshtvarz et al. Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells
Koçer et al. Effects of variable domain orientation on anti‐HER2 single‐chain variable fragment antibody expressed in the Escherichia coli cytoplasm
Lee et al. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells
Lee et al. Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A
Zhang et al. SAC-TRAIL, a novel anticancer fusion protein: expression, purification, and functional characterization
Rönnmark et al. Affibody-β-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol